- In April 2024, DFE Pharma, a global excipient manufacturer with operations in Germany and the Netherlands, expanded its veterinary product line to include species-specific solid oral excipients. These new formulations are designed to enhance palatability, bioavailability, and stability in both companion and livestock animals. This initiative reinforces DFE Pharma’s commitment to addressing the evolving needs of veterinary pharmaceutical manufacturers across the EMEA region with tailored, high-performance excipient solutions
- In March 2024, Roquette Frères (France) announced a strategic collaboration with a Middle Eastern veterinary drug manufacturer to supply plant-based excipients for solid oral dosage forms. The partnership focuses on clean-label, sustainable excipients that meet growing regulatory and consumer demands. Roquette's investment in regional supply chains reflects its strategy to expand veterinary applications of its excipient portfolio across emerging EMEA markets while promoting responsible sourcing and production
- In March 2024, Meggle Group (Germany), a leading producer of lactose-based excipients, launched a new co-processed excipient blend aimed at improving compressibility and stability in veterinary boluses. Designed for high-throughput manufacturing in the livestock segment, this innovation addresses key challenges related to large-dose oral formulations. The product launch demonstrates Meggle’s focus on optimizing animal health drug delivery while maintaining cost-efficiency and product integrity
- In February 2024, Azelis (Belgium), a key distributor of specialty ingredients, expanded its animal health portfolio across North Africa by partnering with leading European excipient manufacturers. This move aims to improve the accessibility of advanced excipients used in veterinary tablets and powders in markets such as Egypt and Morocco. The initiative highlights Azelis’ strategic commitment to supporting local veterinary medicine production with technical expertise and innovative excipient solutions
- In January 2024, BASF SE (Germany) introduced a new line of multifunctional binders and disintegrants tailored for use in solid oral veterinary pharmaceuticals. These excipients, designed for improved functionality under variable storage conditions, are especially suited for climates across Sub-Saharan Africa and the Middle East. The development underscores BASF’s focus on resilience and efficacy in excipient performance, ensuring broader application in challenging environments and expanding access to quality veterinary healthcare across EMEA
